Coenzyme Q10 effects in neurodegenerative disease

References

• GeromelVRotigAMunnichARustinPCoenzyme Q10 depletion is comparatively less detrimental to human cultured skin fibroblasts than respiratory chain complex deficienciesFree Radic Res200236437537912069100
   PubMed Web of Science ®Google Scholar
• MatthewsRTYangLBrowneSBaikMBealMFCoenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effectsProc Natl Acad Sci U S A19989515889288979671775
   PubMed Web of Science ®Google Scholar
• OgawaOZhuXPerryGSmithMAMitochondrial abnormalities and oxidative imbalance in neurodegenerative diseaseSci Aging Knowledge Environ2002200241pe1614603007
   PubMedGoogle Scholar
• StrijksEKremerHPHorstinkMWQ10 therapy in patients with idiopathic Parkinson’s diseaseMol Aspects Med199718SupplS237S2409266528
   PubMed Web of Science ®Google Scholar
• BealMFCoenzyme Q10 administration and its potential for treatment of neurodegenerative diseasesBiofactors199992–426126610416039
   PubMed Web of Science ®Google Scholar
• BonakdarRAGuarneriECoenzyme Q10Am Fam Physician20057261065107016190504
   PubMed Web of Science ®Google Scholar
• RustinPMunnichARotigAQuinone analogs prevent enzymes targeted in Friedreich ataxia from iron-induced injury in vitroBiofactors199992–424725110416037
   PubMed Web of Science ®Google Scholar
• SmithKMMatsonSMatsonWRDose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington’s disease miceBiochim Biophys Acta20061762661662616647250
   PubMed Web of Science ®Google Scholar
• Coenzyme Q10Med Lett Drugs Ther2006481229192016498307
   PubMed Web of Science ®Google Scholar
• ChaturvediRKBealMFMitochondrial approaches for neuroprotectionAnn N Y Acad Sci2008114739541219076459
   PubMed Web of Science ®Google Scholar
• BealMFBioenergetic approaches for neuroprotection in Parkinson’s diseaseAnn Neurol200353Suppl 3S39S47discussion S47–S38.12666097
   PubMed Web of Science ®Google Scholar
• ShultsCWHaasRClinical trials of coenzyme Q10 in neurological disordersBiofactors2005251–411712616873936
   PubMed Web of Science ®Google Scholar
• SharmaSKEl RefaeyHEbadiMComplex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson’s disease and the neuroprotective role of coenzyme Q10Brain Res Bull2006701223216750479
   PubMed Web of Science ®Google Scholar
• SchmelzerCLindnerIRimbachGNiklowitzPMenkeTDoringFFunctions of coenzyme Q10 in inflammation and gene expressionBiofactors2008321–417918319096114
   PubMed Web of Science ®Google Scholar
• BalakrishnanPLeeBJOhDHEnhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systemsInt J Pharm20093741–2667219446761
   PubMed Web of Science ®Google Scholar
• LiuZXArtmannCRelative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery systemAltern Ther Health Med2009152424619284181
   PubMed Web of Science ®Google Scholar
• KalenikovaEIGorodetskayaEAMedvedevOSPharmacokinetics of coenzyme q10Bull Exp Biol Med2008146331331619240848
   PubMed Web of Science ®Google Scholar
• BealMFShultsCWEffects of Coenzyme Q10 in Huntington’s disease and early Parkinson’s diseaseBiofactors2003181–415316114695931
   PubMed Web of Science ®Google Scholar
• ShultsCWFlint BealMSongDFontaineDPilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s diseaseExp Neurol2004188249149415246848
   PubMed Web of Science ®Google Scholar
• QuinziiCMLopezLCNainiADiMauroSHiranoMHuman CoQ10 deficienciesBiofactors2008321–411311819096106
   PubMed Web of Science ®Google Scholar
• DiMauroSQuinziiCMHiranoMMutations in coenzyme Q10 biosynthetic genesJ Clin Invest2007117358758917332886
   PubMed Web of Science ®Google Scholar
• MonteroRPinedaMAracilAClinical, biochemical and molecular aspects of cerebellar ataxia and Coenzyme Q10 deficiencyCerebellum20076211812217510911
   PubMed Web of Science ®Google Scholar
• HuntsmanRJLemireEGDunhamCPHypotonia and infantile spasms: a new phenotype of coenzyme Q10 deficiency?Can J Neurol Sci200936110510819294900
   PubMed Web of Science ®Google Scholar
• DuncanAJBitner-GlindziczMMeunierBA nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondria diseaseAm J Hum Genet200984555856619375058
   PubMed Web of Science ®Google Scholar
• Rodriguez-HernandezACorderoMDSalviatiLCoenzyme Q deficiency triggers mitochondria degradation by mitophagyAutophagy200951193219115482
   PubMed Web of Science ®Google Scholar
• HenchcliffeCBealMFMitochondrial biology and oxidative stress in Parkinson disease pathogenesisNat Clin Pract Neurol200841160060918978800
   PubMedGoogle Scholar
• BealMFMatthewsRTTielemanAShultsCWCoenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged miceBrain Res199878311091149479058
   PubMed Web of Science ®Google Scholar
• KollerWCCersosimoMGNeuroprotection in Parkinson’s disease: an elusive goalCurr Neurol Neurosci Rep20044427728315217541
   PubMedGoogle Scholar
• BealMFNeurochemistry and toxin models in Huntington’s diseaseCurr Opin Neurol1994765425477866587
   PubMed Web of Science ®Google Scholar
• GilleGHungSTReichmannHRauschWDOxidative stress to dopaminergic neurons as models of Parkinson’s diseaseAnn N Y Acad Sci2004101853354015240412
   PubMed Web of Science ®Google Scholar
• CooperJMKorliparaLVHartPEBradleyJLSchapiraAHCoenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapyEur J Neurol200815121371137919049556
   PubMed Web of Science ®Google Scholar
• CooperJMSchapiraAHFriedreich’s Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapyBiofactors2003181–416317114695932
   PubMed Web of Science ®Google Scholar
• CooperJMSchapiraAHFriedreich’s ataxia: coenzyme Q10 and vitamin E therapyMitochondrion20077SupplS127S13517485244
   PubMed Web of Science ®Google Scholar
• ShultsCWHaasRHBealMFA possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s diseaseBiofactors199992–426727210416040
   PubMed Web of Science ®Google Scholar
• StrongMJPatteeGLCreatine and coenzyme Q10 in the treatment of ALSAmyotroph Lateral Scler Other Motor Neuron Disord20001Suppl 4172011466954
   PubMed Web of Science ®Google Scholar
• BogdanovMBRamosLEXuZBealMFElevated “hydroxyl radical” generation in vivo in an animal model of amyotrophic lateral sclerosisJ Neurochem1998713132113249721759
   PubMed Web of Science ®Google Scholar
• ShultsCWHaasRHPassovDBealMFCoenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjectsAnn Neurol19974222612649266740
   PubMed Web of Science ®Google Scholar
• MurataTOhtsukaCTerayamaYIncreased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosisFree Radic Res200842322122518344116
   PubMed Web of Science ®Google Scholar
• BogdanovMMatsonWRWangLMetabolomic profiling to develop blood biomarkers for Parkinson’s diseaseBrain2008131(Pt 2):38939618222993
   PubMed Web of Science ®Google Scholar
• SohmiyaMTanakaMSuzukiYTaninoYOkamotoKYamamotoYAn increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patientsJ Neurol Sci20052281495315607210
   PubMed Web of Science ®Google Scholar
• TohgiHAbeTYamazakiKMurataTIshizakiEIsobeCIncrease in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosisNeurosci Lett1999260320420610076903
   PubMed Web of Science ®Google Scholar
• SchapiraAHMannVMCooperJMAnatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s diseaseJ Neurochem1990556214221452121905
   PubMed Web of Science ®Google Scholar
• HaasRHNasirianFNakanoKLow platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s diseaseAnn Neurol19953767147227778844
   PubMed Web of Science ®Google Scholar
• BeneckeRStrumperPWeissHElectron transfer complexes I and IV of platelets are abnormal in Parkinson’s disease but normal in Parkinson-plus syndromesBrain1993116(Pt 6):145114638293280
   PubMed Web of Science ®Google Scholar
• FerranteRJAndreassenOADedeogluATherapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s diseaseJ Neurosci20022251592159911880489
   PubMed Web of Science ®Google Scholar
• del HoyoPGarcia-RedondoAde BustosFOxidative stress in skin fibroblasts cultures of patients with Huntington’s diseaseNeurochem Res20063191103110916944322
   PubMed Web of Science ®Google Scholar
• HuangHMZhangHXuHGibsonGEInhibition of the alpha-ketoglutarate dehydrogenase complex alters mitochondrial function and cellular calcium regulationBiochim Biophys Acta20031637111912612527416
   PubMed Web of Science ®Google Scholar
• BubberPHaroutunianVFischGBlassJPGibsonGEMitochondrial abnormalities in Alzheimer brain: mechanistic implicationsAnn Neurol200557569570315852400
   PubMed Web of Science ®Google Scholar
• LodiRRajagopalanBBradleyJLMitochondrial dysfunction in Friedreich’s ataxia: from pathogenesis to treatment perspectivesFree Radic Res200236446146612069111
   PubMed Web of Science ®Google Scholar
• LodiRTononCCalabreseVSchapiraAHFriedreich’s ataxia: from disease mechanisms to therapeutic interventionsAntioxid Redox Signal200683–443844316677089
   PubMed Web of Science ®Google Scholar
• HargreavesIPLaneASleimanPMThe coenzyme Q10 status of the brain regions of Parkinson’s disease patientsNeurosci Lett20084471171918840506
   PubMed Web of Science ®Google Scholar
• GotzMEGerstnerAHarthRAltered redox state of platelet coenzyme Q10 in Parkinson’s diseaseJ Neural Transm20001071414810809402
   PubMed Web of Science ®Google Scholar
• SohmiyaMTanakaMTakNWRedox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson’s diseaseJ Neurol Sci2004223216116615337618
   PubMed Web of Science ®Google Scholar
• Jimenez-JimenezFJMolinaJAde BustosFSerum levels of coenzyme Q10 in patients with Parkinson’s diseaseJ Neural Transm2000107217718110847558
   PubMed Web of Science ®Google Scholar
• AndrichJSaftCGerlachMCoenzyme Q10 serum levels in Huntington’s diseaseJ Neural Transm Suppl20046811111615354396
   PubMedGoogle Scholar
• MolinaJAde BustosFJimenez-JimenezFJSerum levels of coenzyme Q10 in patients with amyotrophic lateral sclerosisJ Neural Transm20001078–91021102611041280
   PubMed Web of Science ®Google Scholar
• MoonYLeeKHParkJHGeumDKimKMitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10J Neurochem20059351199120815934940
   PubMed Web of Science ®Google Scholar
• KooncumchooPSharmaSPorterJGovitrapongPEbadiMCoenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neuronsJ Mol Neurosci200628212514116679553
   PubMed Web of Science ®Google Scholar
• SomayajuluMMcCarthySHungMSikorskaMBorowy-BorowskiHPandeySRole of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10Neurobiol Dis200518361862715755687
   PubMed Web of Science ®Google Scholar
• LiGZouLYCaoCMYangESCoenzyme Q10 protects SHSY5Y neuronal cells from beta amyloid toxicity and oxygen-glucose deprivation by inhibiting the opening of the mitochondrial permeability transition poreBiofactors2005251–49710716873934
   PubMed Web of Science ®Google Scholar
• McCarthySSomayajuluMSikorskaMBorowy-BorowskiHPandeySParaquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10Toxicol Appl Pharmacol20042011213115519605
   PubMed Web of Science ®Google Scholar
• Winkler-StuckKWiedemannFRWalleschCWKunzWSEffect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patientsJ Neurol Sci20042201–2414815140604
   PubMed Web of Science ®Google Scholar
• ZeronMMFernandesHBKrebsCPotentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington’s diseaseMol Cell Neurosci200425346947915033175
   PubMed Web of Science ®Google Scholar
• OnoKYamadaMVitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseasesNeurobiol Dis200725244645417169566
   PubMed Web of Science ®Google Scholar
• OnoKHasegawaKNaikiHYamadaMPreformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitroBiochem Biophys Res Commun2005330111111615781239
   PubMed Web of Science ®Google Scholar
• JauslinMLMeierTSmithRAMurphyMPMitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidantsFASEB J200317131972197412923074
   PubMed Web of Science ®Google Scholar
• BealMFHenshawDRJenkinsBGRosenBRSchulzJBCoenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonateAnn Neurol19943668828887998775
   PubMed Web of Science ®Google Scholar
• ClerenCYangLLorenzoBTherapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of ParkinsonismJ Neurochem200810461613162117973981
   PubMed Web of Science ®Google Scholar
• SchillingGCoonfieldMLRossCABorcheltDRCoenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington’s disease transgenic mouse modelNeurosci Lett2001315314915311716985
   PubMed Web of Science ®Google Scholar
• SchillingGSavonenkoAVCoonfieldMLEnvironmental, pharmacological, and genetic modulation of the HD phenotype in transgenic miceExp Neurol2004187113714915081595
   PubMed Web of Science ®Google Scholar
• StackECSmithKMRyuHCombination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington’s disease miceBiochim Biophys Acta20061762337338016364609
   PubMed Web of Science ®Google Scholar
• YangLCalingasanNYWilleEJCombination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseasesJ Neurochem200910951427143919476553
   PubMed Web of Science ®Google Scholar
• YangXYangYLiGWangJYangESCoenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutationJ Mol Neurosci200834216517118181031
   PubMed Web of Science ®Google Scholar
• LiGJackCRYangXFYangESDiet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: an in vivo volume MRI studyBiofactors2008321–416917819096113
   PubMed Web of Science ®Google Scholar
• KipianiKDumontMYuFCoenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer’s disease2009Personal Communication.
   Google Scholar
• SchulzJBHenshawDRMatthewsRTBealMFCoenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicityExp Neurol199513222792837789466
   PubMed Web of Science ®Google Scholar
• ShultsCWBealMFFontaineDNakanoKHaasRHAbsorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patientsNeurology19985037937959521279
   PubMed Web of Science ®Google Scholar
• ShultsCWOakesDKieburtzKEffects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional declineArch Neurol200259101541155012374491
   PubMed Web of Science ®Google Scholar
• A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson diseaseNeurology2007681202817200487
   PubMed Web of Science ®Google Scholar
• StorchACoenzyme Q10 in Parkinson’s disease. Symptomatic or neuroprotective effects?Nervenarzt200778121378138217508194
   PubMed Web of Science ®Google Scholar
• MullerTButtnerTGholipourAFKuhnWCoenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s diseaseNeurosci Lett2003341320120412697283
   PubMed Web of Science ®Google Scholar
• HorstinkMWvan EngelenBGThe effect of coenzyme Q10 therapy in Parkinson disease could be symptomaticArch Neurol200360811701172author reply 1172–117312925381
   PubMedGoogle Scholar
• FeiginAKieburtzKComoPAssessment of coenzyme Q10 tolerability in Huntington’s diseaseMov Disord19961133213238723151
   PubMed Web of Science ®Google Scholar
• KoroshetzWJJenkinsBGRosenBRBealMFEnergy metabolism defects in Huntington’s disease and effects of coenzyme Q10Ann Neurol19974121601659029064
   PubMed Web of Science ®Google Scholar
• A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s diseaseNeurology200157339740411502903
   PubMed Web of Science ®Google Scholar
• HSGPRE2CARE: A dosage ranging trial of coenzyme Q10 in Huntington’s disease and normal subjects [abstract]Cambridge, MAHDF Biennial Symposia2005
   Google Scholar
• HausseAOAggounYBonnetDIdebenone and reduced cardiac hypertrophy in Friedreich’s ataxiaHeart200287434634911907009
   PubMed Web of Science ®Google Scholar
• LodiRHartPERajagopalanBAntioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxiaAnn Neurol200149559059611357949
   PubMed Web of Science ®Google Scholar
• HartPELodiRRajagopalanBAntioxidant treatment of patients with Friedreich ataxia: four-year follow-upArch Neurol200562462162615824263
   PubMedGoogle Scholar
• RinaldiCTucciTMaioneSGiuntaADe MicheleGFillaALow-dose idebenone treatment in Friedreich’s ataxia with and without cardiac hypertrophyJ Neurol200925691434143719363628
   PubMed Web of Science ®Google Scholar
• StamelouMReussAPilatusUShort-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trialMov Disord200823794294918464278
   PubMed Web of Science ®Google Scholar
• FerranteKLShefnerJZhangHTolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALSNeurology200565111834183616344537
   PubMed Web of Science ®Google Scholar
• KaufmannPThompsonJLPLevyGPhase II trial of CoQ10 for ALS finds insufficient evidence to justify phase IIIAnn Neurol200966223524419743457
   PubMed Web of Science ®Google Scholar
• SeninUParnettiLBarbagallo-SangiorgiGIdebenone in senile dementia of Alzheimer type: a multicentre studyArch Gerontol Geriatr199215324926015374364
   PubMed Web of Science ®Google Scholar
• BergamascoBScarzellaLLa CommarePIdebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer typeFunct Neurol1994931611687988944
   PubMedGoogle Scholar
• WeyerGBabej-DolleRMHadlerDHofmannSHerrmannWMA controlled study of 2 doses of idebenone in the treatment of Alzheimer’s diseaseNeuropsychobiology199736273829267856
   PubMed Web of Science ®Google Scholar
• GutzmannHHadlerDSustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre studyJ Neural Transm Suppl1998543013109850939
   PubMedGoogle Scholar
• ThalLJGrundmanMBergJIdebenone treatment fails to slow cognitive decline in Alzheimer’s diseaseNeurology200361111498150214663031
   PubMed Web of Science ®Google Scholar
• TeranEHernandezINietoBTavaraROcampoJECalleACoenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsiaInt J Gynaecol Obstet20091051434519154996
   PubMed Web of Science ®Google Scholar